Zobrazeno 1 - 10
of 32
pro vyhledávání: '"José I, Bernardino"'
Autor:
Ángela B. Moragrega, Carmen Busca, Nadezda Apostolova, Antonio Olveira, Luz Martín-Carbonero, Eulalia Valencia, Victoria Moreno, José I. Bernardino, Marta Abadía, Juan González-García, Juan V. Esplugues, María L. Montes, Ana Blas-García
Publikováno v:
Biomedicines, Vol 12, Iss 7, p 1454 (2024)
Liver fibrosis is a key determinant of the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Its increasing prevalence and a lack of effective treatments make it a major health problem worldwide, particularly in people
Externí odkaz:
https://doaj.org/article/ccced94f0f7d44ff87b23ed0d35a8a03
Autor:
Alejandro De Gea-Grela, Alfredo Maldonado-Barrueco, Clara Cabañuz, Mariana Díaz-Almiron, Alicia Rico, Guillermo Ruíz-Carrascoso, Maria Elena Palacios, Eduardo Martín-Arranz, Raquel Escudero-Nieto, José I Bernardino
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica.
Autor:
Javier, Nogueira López, Luis, Prieto-Tato, Luis, Escosa-García, José I, Bernardino, Eloy, Muñoz, Cristina, Díez, Itzíar, Carrasco, Pablo, Ryan, Sara, Guillén-Martín, José Tomás, Ramos-Amador, María Luisa, Navarro, Africa, Holguín, Talía, Sainz
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 91(4)
An increasing number of women living with perinatally acquired HIV are reaching adulthood and becoming pregnant. Achieving viral suppression is challenging in this population frequently exposed to numerous antiretroviral regimens. This study describe
Autor:
Ignacio Pérez-Valero, Alicia González-Baeza, Miriam Estébanez, María L Montes-Ramírez, Carmen Bayón, Federico Pulido, José I Bernardino, Francisco X Zamora, Susana Monge, Francisco Gaya, María Lagarde, Rafael Rubio, Asunción Hernando, Francisco Arnalich, José R Arribas
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69493 (2013)
In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of n
Externí odkaz:
https://doaj.org/article/8b5b0149e8514f83874ad07b241acab7
Autor:
Juan González-García, Francisco Arnalich, Jesús Mingorance, Ignacio Pérez-Valero, Rosario Perona, Luz Martín-Carbonero, Victoria Moreno, Rocío Montejano, Jose R. Arribas, Eulalia Valencia, Natalia Stella-Ascariz, José I. Bernardino, Laura Pintado Berniches, María Luisa Montes, Susana Monge
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Objective]: To evaluate the in vivo relevance of the inhibitory effect of tenofovir on telomerase activity observed in vitro.
[Design]: Cross-sectional study of HIV-infected patients with suppressed virological replication (HIV RNA
[Method
[Design]: Cross-sectional study of HIV-infected patients with suppressed virological replication (HIV RNA
[Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81eafc98493bc0dbf9500f60b598c88d
http://hdl.handle.net/10261/187847
http://hdl.handle.net/10261/187847
Autor:
Cadiñanos, Julen1,2 (AUTHOR), Rodríguez-Centeno, Javier1,2 (AUTHOR), Montejano, Rocío1,2 (AUTHOR), Esteban-Cantos, Andrés1,2 (AUTHOR), Mena-Garay, Beatriz1 (AUTHOR), Jiménez-González, María1 (AUTHOR), Saiz-Medrano, Gabriel1 (AUTHOR), Miguel, Rosa de1,2 (AUTHOR), Rodríguez-Artalejo, Fernando3,4,5 (AUTHOR), Bernardino, José I1,2 (AUTHOR), Marcelo-Calvo, Cristina1 (AUTHOR), Gutierrez-García, Lucía1 (AUTHOR), Martínez-Martín, Patricia1 (AUTHOR), Vidal, Alejandro Díez1,2 (AUTHOR), Grela, Alejandro de Gea1 (AUTHOR), Ortolá, Rosario3,4 (AUTHOR), Rodés, Berta1,2 (AUTHOR), Arribas, José R1,2 (AUTHOR) joser.arribas@salud.madrid.org
Publikováno v:
Open Forum Infectious Diseases. Oct2024, Vol. 11 Issue 10, p1-7. 7p.
Autor:
José I, Bernardino, Antonio, Antela
Publikováno v:
Enfermedades infecciosas y microbiologia clinica. 33
The efficacy of dolutegravir (DTG) in treatment-naïve patients has been analyzed in the SPRING 1 and 2, SINGLE and FLAMINGO trials, which compared dolutegravir with the agents currently recommended as the drugs of choice in clinical practice guideli
Autor:
Sepúlveda-Crespo, Daniel1,2 (AUTHOR) crispu82@gmail.com, Volpi, Camilla1,3 (AUTHOR) camilla.volpi1@studenti.unimi.it, Amigot-Sánchez, Rafael1 (AUTHOR) rafael.amigot@isciii.es, Yélamos, María Belén4 (AUTHOR) mbyelamos@quim.ucm.es, Díez, Cristina2,5,6 (AUTHOR) jbb4@me.com, Gómez, Julián4 (AUTHOR) jgomezgu@ucm.es, Hontañón, Víctor7,8 (AUTHOR) victor.hontanon@gmail.com, Berenguer, Juan2,5,6 (AUTHOR) juangonzalezgar@gmail.com, González-García, Juan2,7,8 (AUTHOR), Martín-Escolano, Rubén1,2 (AUTHOR) r.martin@isciii.es, Resino, Salvador1,2 (AUTHOR) sresino@isciii.es, Martínez, Isidoro1,2 (AUTHOR) sresino@isciii.es
Publikováno v:
Pharmaceuticals (14248247). Sep2024, Vol. 17 Issue 9, p1152. 15p.
Autor:
Juan García, Puig, María A Martínez, López, Teresa Sancho, Bueso, José I, Bernardino, Rosa Torres, Jiménez
Publikováno v:
Cardiovascular drugs and therapy. 16(6)
Angiotensin II (AII) receptor blockers offer an alternative means of blocking the renin-angiotensin-aldosterone system (RAAS) to angiotensin converting enzyme (ACE) inhibitors. Being highly selective for the AII receptor subtype AT(1), AII receptor b